Semaglutide dosing schedule: the approved escalation protocol, Ozempic vs Wegovy differences, and why the 16-week timeline exists.
Semaglutide's dose escalation protocol — the mandatory step-up from 0.25 mg through intermediate doses to the 2.4 mg maintenance dose — is one of the most widely searched questions about GLP-1 agonist therapy. The escalation is not arbitrary: it is the evidence-based approach to building GLP-1 receptor tolerance in the area postrema while allowing GI adaptation, and diverging from it predictably increases nausea and discontinuation risk.
- Wegovy (semaglutide for obesity): 5-step escalation over 16 weeks to 2.4 mg/week maintenance.
- Ozempic (semaglutide for type 2 diabetes): escalation to 1 mg or 2 mg/week maintenance — different product with different indications and pens.
- The 0.25 mg starting dose has no significant GLP-1 receptor effect at the hypothalamus — it serves purely to reduce GI adverse events during initiation.
- Patients who tolerate a dose for 4 weeks escalate; those who don't can hold the current dose for additional weeks before escalating.
- Missing a dose: if ≤5 days missed, inject as soon as remembered. If >5 days missed, skip and resume on next scheduled day.
- Compounded semaglutide dosing should follow the same escalation logic — the molecule and its GI side effects are the same.
Wegovy dose escalation: the approved protocol
The FDA-approved Wegovy dosing schedule for obesity treatment:
| Weeks | Weekly dose | Purpose |
|---|---|---|
| Weeks 1–4 | 0.25 mg | GI tolerance initiation (not therapeutic dose) |
| Weeks 5–8 | 0.5 mg | Low therapeutic range |
| Weeks 9–12 | 1.0 mg | Moderate therapeutic range |
| Weeks 13–16 | 1.7 mg | Near-maintenance range |
| Week 17+ | 2.4 mg | Maintenance dose |
If the patient cannot tolerate escalation to 2.4 mg due to side effects, the 1.7 mg dose can be maintained as a reduced maintenance dose. The 2.4 mg dose produced the primary STEP-1 trial results (~15% weight loss at 68 weeks); lower doses produce proportionally less weight loss.
Why the escalation timeline was chosen
The 4-week intervals at each dose step were determined empirically from Phase II dose-finding studies. The rationale:
- Area postrema GLP-1R desensitization: the brainstem emesis center requires approximately 3–4 weeks at a given dose to substantially reduce nausea response. Escalating faster does not allow this adaptation.
- Gastric accommodation: the pyloric and enteric nervous system adapts to reduced gastric emptying over weeks. Faster escalation overwhelms this adaptation.
- Weight loss onset: the 0.25 mg and 0.5 mg doses are subtherapeutic for weight loss; the 1 mg and above doses begin producing meaningful GLP-1R occupancy at hypothalamic satiety centers.
Studies that used accelerated escalation schedules consistently showed higher nausea rates and higher discontinuation rates without proportional improvements in weight loss — confirming that the 4-week steps represent an optimized tolerance-building protocol (PMID: 33567185).
Ozempic vs Wegovy: different products, different dose targets
A common source of confusion is the difference between Ozempic and Wegovy:
| Feature | Ozempic | Wegovy |
|---|---|---|
| Indication | Type 2 diabetes | Chronic weight management |
| Approved max dose | 2 mg/week | 2.4 mg/week |
| Pen types | 0.25/0.5 mg; 1 mg; 2 mg pens | 0.25 mg; 0.5 mg; 1 mg; 1.7 mg; 2.4 mg pens |
| Escalation to maintenance | 8–12 weeks typical | 16 weeks |
These are the same semaglutide molecule — differences are in approved indication, maintenance dose, pen design, and labeling. Off-label use of Ozempic for weight loss at 2.4 mg (by combining pens) does not have specific safety or efficacy data vs. Wegovy at 2.4 mg, but the pharmacology is identical at equivalent doses.
Missed dose management
The FDA-approved missed dose guidance for Wegovy:
- If ≤5 days since the scheduled dose: inject the missed dose as soon as possible, then resume the normal weekly schedule.
- If >5 days since the scheduled dose: skip the missed dose, and take the next dose on the regularly scheduled day.
- Do not take two doses in the same week to make up for a missed dose.
Frequent missed doses disrupt GLP-1R occupancy and may reduce weight-loss efficacy. If a patient has been off semaglutide for more than 2 weeks, some clinicians recommend restarting at a lower dose to reduce GI adverse events on re-initiation, though this is not standardized in prescribing information.
Compounded semaglutide: same pharmacology, same escalation logic
Compounded semaglutide (from 503B compounding pharmacies) contains the same active molecule as Wegovy and Ozempic, and therefore the same GI mechanism and same tolerance-building requirement applies. The dose escalation protocol should follow the same schedule. The FDA's concerns about compounded semaglutide relate to quality control, not to pharmacology — the escalation logic is identical because the mechanism is identical.